0001415889-24-002096.txt : 20240131
0001415889-24-002096.hdr.sgml : 20240131
20240131193433
ACCESSION NUMBER: 0001415889-24-002096
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240129
FILED AS OF DATE: 20240131
DATE AS OF CHANGE: 20240131
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jorgensen Nathan D.
CENTRAL INDEX KEY: 0001842523
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39979
FILM NUMBER: 24584573
MAIL ADDRESS:
STREET 1: C/O VOR BIOPHARMA INC.
STREET 2: 100 CAMBRIDGEPARK DRIVE, SUITE 400
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vor Biopharma Inc.
CENTRAL INDEX KEY: 0001817229
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 101
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-655-6580
MAIL ADDRESS:
STREET 1: 100 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 101
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
4
1
form4-02012024_120227.xml
X0508
4
2024-01-29
0001817229
Vor Biopharma Inc.
VOR
0001842523
Jorgensen Nathan D.
C/O VOR BIOPHARMA INC.
100 CAMBRIDGEPARK DRIVE, SUITE 101
CAMBRIDGE
MA
02140
false
true
false
false
CHIEF FINANCIAL OFFICER
0
Common Stock
2024-01-29
4
A
0
50000
0
A
198449
D
Employee Stock Option (right to buy)
2.41
2024-01-29
4
A
0
100000
0
A
2034-01-28
Common Stock
100000
100000
D
Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2024, subject to the Reporting Person's continued service as of each such date.
Includes 2,802 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan.
The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.
/s/ Katie Kazem, Attorney-in-Fact
2024-01-31